Abstract The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer....
Tumor-infiltrating lymphocytes (TILs) develop as manifestations of the recognition and defense again...
The composition of tumor-infiltrating lymphocytes (TIL) reflects biology and immunogenicity of cance...
Abstract Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and lo...
The immune response against cancer is orchestrated by various parameters and site-dependent specific...
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention on tumor-inf...
Interactions between the immune system and tumors have been among the highlights of present immunolo...
Despite significant progress in cancer diagnostics and development of novel therapeutic regimens, su...
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. The...
Tumor immunology consists of two essential concepts: immune surveillance, which specifies the host i...
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan f...
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse ca...
The status of a host's immune response influences both the development and progression of a malignan...
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse ca...
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tum...
International audienceγδ T-cells contribute to the immune response against many tumor types through ...
Tumor-infiltrating lymphocytes (TILs) develop as manifestations of the recognition and defense again...
The composition of tumor-infiltrating lymphocytes (TIL) reflects biology and immunogenicity of cance...
Abstract Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and lo...
The immune response against cancer is orchestrated by various parameters and site-dependent specific...
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention on tumor-inf...
Interactions between the immune system and tumors have been among the highlights of present immunolo...
Despite significant progress in cancer diagnostics and development of novel therapeutic regimens, su...
Cancer immunotherapy may become a major treatment backbone in many cancers over the next decade. The...
Tumor immunology consists of two essential concepts: immune surveillance, which specifies the host i...
Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan f...
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse ca...
The status of a host's immune response influences both the development and progression of a malignan...
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse ca...
T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in resected tum...
International audienceγδ T-cells contribute to the immune response against many tumor types through ...
Tumor-infiltrating lymphocytes (TILs) develop as manifestations of the recognition and defense again...
The composition of tumor-infiltrating lymphocytes (TIL) reflects biology and immunogenicity of cance...
Abstract Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and lo...